{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T14:33:22Z","timestamp":1768833202951,"version":"3.49.0"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2013,1,31]],"date-time":"2013-01-31T00:00:00Z","timestamp":1359590400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"DOI":"10.1371\/journal.ppat.1003155","type":"journal-article","created":{"date-parts":[[2013,1,31]],"date-time":"2013-01-31T21:54:21Z","timestamp":1359669261000},"page":"e1003155","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":43,"title":["Preclinical Therapy of Disseminated HER-2+ Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus"],"prefix":"10.1371","volume":"9","author":[{"given":"Patrizia","family":"Nanni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Gatta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Menotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"De Giovanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianna","family":"Ianzano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Palladini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Grosso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Dall'Ora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Croci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giordano","family":"Nicoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"Landuzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuela","family":"Iezzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"Campadelli-Fiume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier-Luigi","family":"Lollini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,1,31]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrmicro1927","article-title":"Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded","volume":"6","author":"R Cattaneo","year":"2008","journal-title":"Nat Rev Microbiol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/rmv.691","article-title":"Rethinking herpes simplex virus: the way to oncolytic agents","volume":"21","author":"G Campadelli-Fiume","year":"2011","journal-title":"Rev Med Virol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"SJ Russell","year":"2012","journal-title":"Nat Biotechnol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.1128\/JVI.02725-05","article-title":"A herpes simplex virus recombinant that exhibits a single-chain antibody to HER2\/neu enters cells through the mammary tumor receptor, independently of the gD receptors","volume":"80","author":"L Menotti","year":"2006","journal-title":"J Virol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"10153","DOI":"10.1128\/JVI.01133-08","article-title":"Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2","volume":"82","author":"L Menotti","year":"2008","journal-title":"J Virol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"9039","DOI":"10.1073\/pnas.0812268106","article-title":"Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells","volume":"106","author":"L Menotti","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/mt.2012.22","article-title":"Replication-competent Herpes Simplex Virus Retargeted to HER2 as Therapy for High-grade Glioma","volume":"20","author":"E Gambini","year":"2012","journal-title":"Mol Ther"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.4161\/cc.8.18.9368","article-title":"Oncolytic herpes virus retargeted to HER-2","volume":"8","author":"PL Lollini","year":"2009","journal-title":"Cell Cycle"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/cgt.2012.62","article-title":"Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice","volume":"19","author":"E Reisoli","year":"2012","journal-title":"Cancer Gene Ther"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/rmv.546","article-title":"The multipartite system that mediates entry of herpes simplex virus into the cell","volume":"17","author":"G Campadelli-Fiume","year":"2007","journal-title":"Rev Med Virol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"10516","DOI":"10.1073\/pnas.92.23.10516","article-title":"Association of a M(r) 90,000 phosphoprotein with protein kinase PKR in cells exhibiting enhanced phosphorylation of translation initiation factor eIF-2 alpha and premature shutoff of protein synthesis after infection with gamma 134.5- mutants of herpes simplex virus 1","volume":"92","author":"J Chou","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref12","first-page":"1502","article-title":"Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors","volume":"57","author":"S Andreansky","year":"1997","journal-title":"Cancer Res"},{"key":"ref13","unstructured":"Odunsi K, Pejovic T, Anderson ML (2008) Gynecologic cancers. In: DeVita DV, Lawrence TS, Rosenberg SA, editors. Principles & Practice of Oncology. Philadelphia: Lippincott. pp. 1487\u20131592."},{"key":"ref14","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrc1670","article-title":"Breast cancer metastasis: markers and models","volume":"5","author":"B Weigelt","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1158\/0008-5472.CAN-08-1056","article-title":"Trastuzumab-induced HER reprogramming in \u201cresistant\u201d breast carcinoma cells","volume":"69","author":"M Narayan","year":"2009","journal-title":"Cancer Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.ymthe.2004.08.013","article-title":"Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer","volume":"10","author":"TJ Shaw","year":"2004","journal-title":"Mol Ther"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.ejca.2009.11.018","article-title":"High metastatic efficiency of human sarcoma cells in Rag2\/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy","volume":"46","author":"P Nanni","year":"2010","journal-title":"Eur J Cancer"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e39626","DOI":"10.1371\/journal.pone.0039626","article-title":"Multiorgan metastasis of human HER-2(+) breast cancer in Rag2(\u2212)\/(\u2212);Il2rg(\u2212)\/(\u2212) mice and treatment with PI3K inhibitor","volume":"7","author":"P Nanni","year":"2012","journal-title":"PLoS One"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5858\/2010-0454-RAR.1","article-title":"HER2: biology, detection, and clinical implications","volume":"135","author":"C Gutierrez","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial","volume":"379","author":"J Baselga","year":"2012","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"J Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1016\/j.molimm.2009.05.009","article-title":"Cancer resistance to complement-dependent cytotoxicity (CDC): Problem-oriented research and development","volume":"46","author":"D Gancz","year":"2009","journal-title":"Mol Immunol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ctrv.2011.06.002","article-title":"Activity and resistance of trastuzumab according to different clinical settings","volume":"38","author":"E Tagliabue","year":"2012","journal-title":"Cancer Treat Rev"},{"key":"ref24","first-page":"2306","article-title":"Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype","volume":"62","author":"X Fu","year":"2002","journal-title":"Cancer Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"8301","DOI":"10.1158\/0008-5472.CAN-07-1499","article-title":"Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity","volume":"67","author":"J Veerapong","year":"2007","journal-title":"Cancer Res"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1128\/JVI.80.3.1110-1120.2006","article-title":"Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1","volume":"80","author":"KD Smith","year":"2006","journal-title":"J Virol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"9371","DOI":"10.1158\/0008-5472.CAN-07-0674","article-title":"Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses","volume":"67","author":"S Varghese","year":"2007","journal-title":"Cancer Res"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/cgt.2008.83","article-title":"Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice","volume":"16","author":"Y Kulu","year":"2009","journal-title":"Cancer Gene Ther"},{"key":"ref29","first-page":"757","article-title":"Oncolytic herpes simplex virus treatment of metastatic breast cancer","volume":"40","author":"J Wang","year":"2012","journal-title":"Int J Oncol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/sj.cgt.7701033","article-title":"An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer","volume":"14","author":"X Fu","year":"2007","journal-title":"Cancer Gene Ther"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1089\/hum.2006.17.1214","article-title":"Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver","volume":"17","author":"N Kemeny","year":"2006","journal-title":"Hum Gene Ther"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/mt.2008.240","article-title":"A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer","volume":"17","author":"Y Fong","year":"2009","journal-title":"Mol Ther"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"15s [Abstract 4089]","DOI":"10.1200\/jco.2009.27.15_suppl.4089","article-title":"Phase II efficacy results using an oncolytic herpes simplex virus (NV1020) in patients with colorectal cancer metastatic to liver (mCRC)","volume":"27","author":"SK Geevarghese","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/ijc.22680","article-title":"Treatment of implanted mammary tumors with recombinant vesicular stomatitis virus targeted to Her2\/neu","volume":"121","author":"I Bergman","year":"2007","journal-title":"Int J Cancer"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2174\/156800907780058871","article-title":"HSV-1 viral oncolysis and molecular imaging with PET","volume":"7","author":"D Kuruppu","year":"2007","journal-title":"Curr Cancer Drug Targets"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1089\/hum.1998.9.11-1543","article-title":"Mapping the in vivo distribution of herpes simplex virions","volume":"9","author":"D Schellingerhout","year":"1998","journal-title":"Hum Gene Ther"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1038\/sj.bjc.6600573","article-title":"Sensitive PCR method for the detection and real-time quantification of human cells in xenotransplantation systems","volume":"87","author":"M Becker","year":"2002","journal-title":"Br J Cancer"}],"container-title":["PLoS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.ppat.1003155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T03:21:19Z","timestamp":1644204079000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1003155"}},"subtitle":[],"editor":[{"given":"David M.","family":"Knipe","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,1,31]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,1,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1003155","relation":{},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,31]]}}}